Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy Post author: Post published:April 14, 2024 Post category:uncategorized In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. You Might Also Like 10 Everyday Things That Spike Blood Sugar October 12, 2023 Optimize postprandial glycemic control with tailored exercise prescriptions April 18, 2024 Study finds AI-driven eye exams increase screening rates for youth with diabetes January 14, 2024